CoChat
Sign Up
Cited by 394

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Clinical and translational advances in ovarian cancer therapy

Konstantinopoulos, Panagiotis A., Matulonis, Ursula A.·2023·Nature Cancer
DOI 10.1038/s43018-023-00617-9
Open this paper in CoChat — free account

Abstract

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and is initially very responsive to platinum-based chemotherapy. However, the majority of patients relapse following initial surgery and chemotherapy, highlighting the urgent need to develop new therapeutic strategies. In this Review, we outline the main therapeutic principles behind the management of newly diagnosed and recurrent epithelial ovarian cancer and discuss the current landscape of targeted and immune-based approaches.

Overview

Integrity signals

Registry

Crossref · 10.1038/s43018-023-00617-9

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 10 references

Research works printed but not linked: 189

  1. Dalmartello, M. et al. European cancer mortality predictions for the year 2022 with focus on ovarian cancer. Ann. Oncol. 33, 330–339 (2022). · DOI
  2. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022). · DOI · Paper page
  3. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011). · DOI · Paper page
  4. Gershenson, D. M. et al. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol. Oncol. 165, 560–567 (2022). · DOI
  5. Hollis, R. L. et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nat. Commun. 11, 4995 (2020). · DOI
  6. Jones, S. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228–231 (2010). · DOI
  7. Morice, P., Gouy, S. & Leary, A. Mucinous ovarian carcinoma. N. Engl. J. Med. 380, 1256–1266 (2019). · DOI
  8. Parra-Herran, C. et al. p53, mismatch repair protein, and POLE abnormalities in ovarian clear cell carcinoma: an outcome-based clinicopathologic analysis. Am. J. Surg. Pathol. 43, 1591–1599 (2019). · DOI
  9. Norquist, B. M. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2, 482–490 (2016). · DOI
  10. Armstrong, D. K. et al. NCCN Guidelines® Insights: ovarian cancer, version 3.2022. J. Natl Compr. Canc. Netw. 20, 972–980 (2022). · DOI
  11. Konstantinopoulos, P. A. et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J. Clin. Oncol. 38, 1222–1245 (2020). · DOI · Paper page
  12. Hollis, R. L. et al. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo–ovarian high-grade serous carcinoma. Br. J. Cancer 127, 1034–1042 (2022). · DOI
  13. Gotoh, O. et al. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat. Commun. 10, 4965 (2019). · DOI
  14. Koh, H. H., Park, E. & Kim, H. S. Mesonephric-like adenocarcinoma of the ovary: clinicopathological and molecular characteristics. Diagnostics 12, 326 (2022). · DOI
  15. Goff, B. Symptoms associated with ovarian cancer. Clin. Obstet. Gynecol. 55, 36–42 (2012). · DOI
  16. Prat, J. & Oncology, F. C. O. G. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 124, 1–5 (2014). · DOI
  17. Coleridge, S. L., Bryant, A., Kehoe, S. & Morrison, J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst. Rev. 7, CD005343 (2021).
  18. Vergote, I., Amant, F. & Leunen, K. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists. Gynecol. Oncol. 119, 1–2 (2010). · DOI
  19. Wright, A. A. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 3460–3473 (2016). · DOI
  20. Clamp, A. R. et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 23, 919–930 (2022). · DOI
  21. du Bois, A. et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J. Clin. Oncol. 28, 4162–4169 (2010). · DOI
  22. McGuire, W. P. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1–6 (1996). · DOI
  23. Ozols, R. F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194–3200 (2003). · DOI
  24. Chan, J. K. et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N. Engl. J. Med. 374, 738–748 (2016). · DOI
  25. Pignata, S. et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 15, 396–405 (2014). · DOI
  26. Katsumata, N. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 14, 1020–1026 (2013). · DOI
  27. Armstrong, D. K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34–43 (2006). · DOI
  28. van Driel, W. J., Koole, S. N. & Sonke, G. S. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med. 378, 1363–1364 (2018). · DOI
  29. Bell, J. et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 102, 432–439 (2006). · DOI
  30. Chan, J. K. et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol. Oncol. 116, 301–306 (2010). · DOI
  31. Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473–2483 (2011). · DOI
  32. Oza, A. M. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 16, 928–936 (2015). · DOI
  33. Tewari, K. S. et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol. 37, 2317–2328 (2019). · DOI
  34. Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1721–1731 (2021). · DOI
  35. DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J. Clin. Oncol. 41, 609–617 (2022). · DOI · Paper page
  36. Gonzalez-Martin, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019). · DOI
  37. Ray-Coquard, I. L. et al. Final Overall Survival (OS) Results from the Phase III PAOLA-1/ENGOT-ov25 Trial Evaluating Maintenance Olaparib (Ola) Plus Bevacizumab (Bev) in Patients (Pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC) (ESMO, 2022). · DOI
  38. Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416–2428 (2019). · DOI
  39. Gershenson, D. M. et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J. Clin. Oncol. 35, 1103–1111 (2017). · DOI
  40. Markman, M. et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J. Clin. Oncol. 22, 3120–3125 (2004). · DOI
  41. Vergote, I. et al. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 23, e374–e384 (2022). · DOI
  42. Krause, D. & Richardson, D. L. Is there a role for secondary debulking in ovarian cancer? A review of the current literature. Curr. Opin. Obstet. Gynecol. 35, 1–5 (2022). · DOI
  43. Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039–2045 (2012). · DOI
  44. Coleman, R. L. et al. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18, 779–791 (2017). · DOI
  45. Pujade-Lauraine, E. et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28, 3323–3329 (2010). · DOI
  46. Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949–1961 (2017). · DOI
  47. Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154–2164 (2016). · DOI
  48. Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 620–631 (2021). · DOI
  49. Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017). · DOI
  50. Matulonis, U. A. The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: lessons being learned and new questions emerging from phase 3 trial long-term outcome data. Gynecol. Oncol. 167, 401–403 (2022). · DOI
  51. Tew, W. P., Lacchetti, C., Kohn, E. C. & PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO Guideline Rapid Recommendation Update. J. Clin. Oncol. 40, 3878–3881 (2022). · DOI
  52. Kwan, T. T. et al. Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib. JAMA Oncol. 7, 1772–1781 (2021). · DOI
  53. Matulonis, U. et al. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer. Gynecol. Oncol. 162, S24–S25 (2021). · DOI
  54. O’Malley, D. M. et al. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol. Oncol. 167, 404–413 (2022). · DOI
  55. Poveda, A. M. et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J. Clin. Oncol. 33, 3836–3838 (2015). · DOI
  56. Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302–1308 (2014). · DOI
  57. Matulonis, U. A. et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (SGO, 2022). · DOI
  58. Matulonis, U. A. et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor α expression: results from the SORAYA study. J. Clin. Oncol. 41, 2436–2445 (2023). · DOI
  59. Buechel, M. et al. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann. Oncol. 30, 721–732 (2019). · DOI
  60. Castells, M. C. et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J. Allergy Clin. Immunol. 122, 574–580 (2008). · DOI
  61. Oza, A. M. et al. Overall Survival Results from ARIEL4: A Phase III Study Assessing Rucaparib vs Chemotherapy in Patients with Advanced, Relapsed Ovarian Carcinoma and a Deleterious BRCA1/2 Mutation (ESMO, 2022). · DOI
  62. Leath III, C. et al. Overall Survival by Number of Prior Lines of Chemotherapy in Patients with BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer Receiving Olaparib Treatment or Non-Platinum Chemotherapy in SOLO3 (IGCS, 2022). · DOI
  63. Disis, M. L. et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5, 393–401 (2019). · DOI
  64. Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080–1087 (2019). · DOI
  65. Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol. 39, 3671–3681 (2021). · DOI
  66. Konstantinopoulos, P. A. & Cannistra, S. A. Immune checkpoint inhibitors in ovarian cancer: can we bridge the gap between imagynation and reality? J. Clin. Oncol. 39, 1833–1838 (2021). · DOI
  67. Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1275–1289 (2021). · DOI
  68. Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J. Clin. Oncol. 39, 1842–1855 (2021). · DOI
  69. Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22, 1034–1046 (2021). · DOI
  70. Sia, T. Y. et al. Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. Int. J. Gynecol. Cancer 32, 1017–1024 (2022). · DOI
  71. Strickland, K. C. et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587–13598 (2016). · DOI
  72. Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017). · DOI
  73. Datta, M., Coussens, L. M., Nishikawa, H., Hodi, F. S. & Jain, R. K. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am. Soc. Clin. Oncol. Educ. Book 39, 165–174 (2019). · DOI
  74. Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325–340 (2018). · DOI · Paper page
  75. Kandalaft, L. E., Odunsi, K. & Coukos, G. Immune therapy opportunities in ovarian cancer. Am. Soc. Clin. Oncol. Educ. Book 40, 1–13 (2020).
  76. Sarivalasis, A., Morotti, M., Mulvey, A., Imbimbo, M. & Coukos, G. Cell therapies in ovarian cancer. Ther. Adv. Med. Oncol. 13, 17588359211008399 (2021). · DOI
  77. Yan, W., Hu, H. & Tang, B. Advances of chimeric antigen receptor T cell therapy in ovarian cancer. OncoTargets Ther. 12, 8015–8022 (2019). · DOI
  78. Odunsi, K. et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 63, 6076–6083 (2003).
  79. Chen, J. et al. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol. Immunother. 72, 409–425 (2022). · DOI
  80. Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006). · DOI
  81. Cohen, C. A., Shea, A. A., Heffron, C. L., Schmelz, E. M. & Roberts, P. C. Interleukin-12 immunomodulation delays the onset of lethal peritoneal disease of ovarian cancer. J. Interferon Cytokine Res. 36, 62–73 (2016). · DOI
  82. Thaker, P. H. et al. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: an NRG Oncology/Gynecologic Oncology Group study. Gynecol. Oncol. 147, 283–290 (2017). · DOI
  83. Thaker, P. H. et al. GEN-1 in combination with neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer: a phase I dose-escalation study. Clin. Cancer Res. 27, 5536–5545 (2021). · DOI
  84. Lopes, J. E. et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J. Immunother. Cancer 8, e000673 (2020). · DOI
  85. Lopes, J. E. et al. The combination of a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, and the angiogenesis inhibitor lucitanib enhances antitumor activity. Cancer Res. 80, 2202 (2020). · DOI
  86. Vaishampayan, U. N. et al. Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. J. Clin. Oncol. 40, 2500 (2022). · DOI
  87. Brewer, M. et al. Front-line chemo-immunotherapy with carboplatin–paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: a randomized phase II study. Gynecol. Oncol. 156, 523–529 (2020). · DOI
  88. Sabbatini, P. et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—the MIMOSA study. J. Clin. Oncol. 31, 1554–1561 (2013). · DOI
  89. Zhang, Y., Zhang, L., Zhao, Y., Wang, S. & Feng, L. Efficacy and safety of gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: a systematic review and meta-analysis of randomized controlled trials. Front. Oncol. 12, 945867 (2022). · DOI
  90. Rocconi, R. P. et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 21, 1661–1672 (2020). · DOI
  91. Rocconi, R. P. et al. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol. Oncol. 161, 676–680 (2021). · DOI
  92. Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A. & D’Andrea, A. D. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 7, 675–693 (2017). · DOI
  93. Drew, Y. et al. Phase II Study of Olaparib 1 Durvalumab (MEDIOLA): Updated Results in Germline BRCA-Mutated Platinum-Sensitive Relapsed (PSR) Ovarian Cancer (OC) (ESMO, 2019). · DOI
  94. Drew, Y. et al. Phase II Study of Olaparib (O) plus Durvalumab (D) and Bevacizumab (B) (MEDIOLA): Initial Results in Patients (pts) with Non-Germline BRCA-Mutated (Non-gBRCAm) Platinum Sensitive Relapsed (PSR) Ovarian Cancer (OC) (ESMO, 2020). · DOI
  95. Konstantinopoulos, P. A. et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 5, 1141–1149 (2019). · DOI
  96. Wang, Q. et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat. Commun. 13, 3022 (2022). · DOI
  97. Mehta, A. K. et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat. Cancer 2, 66–82 (2021). · DOI
  98. Zsiros, E. et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 7, 78–85 (2021). · DOI
  99. Cadoo, K. A. et al. A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC). J. Clin. Oncol. 37, 5511 (2019). · DOI
  100. Stover, E. H., Fuh, K., Konstantinopoulos, P. A., Matulonis, U. A. & Liu, J. F. Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol. Oncol. 159, 887–898 (2020). · DOI
  101. Farkkila, A. et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat. Commun. 11, 1459 (2020). · DOI
  102. Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517–525 (2017). · DOI · Paper page
  103. Cong, K. et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol. Cell 81, 3227–3144 (2021). · DOI
  104. Hurley, R. M. et al. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer 3, zcab028 (2021). · DOI
  105. Kondrashova, O. et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 7, 984–998 (2017). · DOI
  106. Kondrashova, O. et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat. Commun. 9, 3970 (2018). · DOI
  107. Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008–3015 (2011). · DOI
  108. Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688–695 (2010). · DOI · Paper page
  109. Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243–254 (2010). · DOI · Paper page
  110. Konstantinopoulos, P. A. et al. EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). Future Oncol. 18, 3481–3492 (2022). · DOI
  111. Veneris, J. T., Matulonis, U. A., Liu, J. F. & Konstantinopoulos, P. A. Choosing wisely: selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecol. Oncol. 156, 488–497 (2020). · DOI
  112. Murai, J. et al. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J. Pharmacol. Exp. Ther. 349, 408–416 (2014). · DOI
  113. Ngoi, N. Y. L., Leo, E., O’Connor, M. J. & Yap, T. A. Development of next-generation poly(ADP-ribose) polymerase 1-selective inhibitors. Cancer J. 27, 521–528 (2021). · DOI
  114. Illuzzi, G. et al. Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper. Clin. Cancer Res. 28, 4724–4736 (2022). · DOI
  115. Yap, T. A. et al. Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations. Cancer Res. 82, CT007 (2022). · DOI
  116. Ceccaldi, R. et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature 518, 258–262 (2015). · DOI
  117. Mateos-Gomez, P. A. et al. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination. Nature 518, 254–257 (2015). · DOI
  118. Beagan, K. et al. Drosophila DNA polymerase θ utilizes both helicase-like and polymerase domains during microhomology-mediated end joining and interstrand crosslink repair. PLoS Genet. 13, e1006813 (2017). · DOI
  119. Pignata, S. et al. Chemotherapy in epithelial ovarian cancer. Cancer Letters 303, 73–83 (2011). · DOI
  120. Johnson, N. et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc. Natl Acad. Sci. USA 110, 17041–17046 (2013). · DOI
  121. Sanij, E. et al. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nat. Commun. 11, 2641 (2020). · DOI
  122. Lim, K. S. et al. USP1 is required for replication fork protection in BRCA1-deficient tumors. Mol. Cell 72, 925–941 (2018). · DOI
  123. Murai, J. et al. The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Mol. Cell. Biol. 31, 2462–2469 (2011). · DOI
  124. Curtin, N. J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 12, 801–817 (2012). · DOI · Paper page
  125. Karst, A. M. et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 74, 1141–1152 (2014). · DOI
  126. Etemadmoghadam, D. et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc. Natl Acad. Sci. USA 110, 19489–19494 (2013). · DOI
  127. Aziz, D. et al. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes. Gynecol. Oncol. 151, 327–336 (2018). · DOI
  128. da Costa, A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D. & Konstantinopoulos, P. A. Targeting replication stress in cancer therapy. Nat. Rev. Drug Discov. 22, 38–58 (2022). · DOI
  129. Au-Yeung, G., Mileshkin, L. & Bowtell, D. D. L. CCNE1 amplification as a therapeutic target. J. Clin. Oncol. 41, 1770–1773 (2023). · DOI
  130. Lee, K. Y., Chung, K. Y. & Koo, H. S. The involvement of FANCM, FANCI, and checkpoint proteins in the interstrand DNA crosslink repair pathway is conserved in C. elegans. DNA Repair 9, 374–382 (2010). · DOI
  131. Dykhuizen, E. C. et al. BAF complexes facilitate decatenation of DNA by topoisomerase IIα. Nature 497, 624–627 (2013). · DOI
  132. Konstantinopoulos, P. A. et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 957–968 (2020). · DOI
  133. Konstantinopoulos, P. A. et al. A replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat. Commun. 12, 5574 (2021). · DOI
  134. Lheureux, S. et al. A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: a trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia. J. Clin. Oncol. 37, 5518 (2019). · DOI
  135. Ray Chaudhuri, A. et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 535, 382–387 (2016). · DOI
  136. Murai, J. et al. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 7, 76534–76550 (2016). · DOI
  137. D’Andrea, A. D. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair 71, 172–176 (2018). · DOI
  138. Yazinski, S. A. et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 31, 318–332 (2017). · DOI
  139. Tang, Z. et al. ATR inhibition induces CDK1–SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer. Clin. Cancer Res. 27, 4898–4909 (2021). · DOI
  140. Sieh, W. et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 14, 853–862 (2013). · DOI
  141. George, A. et al. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. BMC Cancer 17, 456 (2017). · DOI
  142. Stanley, B. et al. Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. Gynecol. Oncol. 152, 278–285 (2019). · DOI
  143. ElNaggar, A. et al. Genomic profiling in low grade serous ovarian cancer: identification of novel markers for disease diagnosis and therapy. Gynecol. Oncol. 167, 306–313 (2022). · DOI
  144. Gershenson, D. M., Sun, C. C. & Wong, K. K. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br. J. Cancer 113, 1254–1258 (2015). · DOI
  145. Moujaber, T. et al. New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocr. Relat. Cancer 29, R1–R16 (2021). · DOI
  146. Gershenson, D. M. et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet 399, 541–553 (2022). · DOI
  147. Monk, B. J. et al. MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J. Clin. Oncol. 38, 3753–3762 (2020). · DOI
  148. Grisham, R. N. et al. Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer. J. Clin. Oncol. 33, 4099–4105 (2015). · DOI
  149. Mak, G. et al. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. Br. J. Cancer 120, 975–981 (2019). · DOI
  150. Paradis, J. S. et al. Synthetic lethal screens reveal cotargeting FAK and MEK as a multimodal precision therapy for GNAQ-driven uveal melanoma. Clin. Cancer Res. 27, 3190–3200 (2021). · DOI
  151. Banerjee, S. et al. Phase I Study of the Combination of the Dual RAF/MEK Inhibitor VS-6766 and the FAK Inhibitor Defactinib: Results of Efficacy in Low Grade Serous Ovarian Cancer (ESMO, 2021). · DOI · Paper page
  152. Banerjee, S. N. et al. ENGOT-ov60/GOG3052/RAMP 201: a phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC). J. Clin. Oncol. 39, TPS5603 (2021). · DOI
  153. Solomon, B. et al. Abstract CT033: safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors. Cancer Res. 83, CT033 (2023). · DOI
  154. Zoeller, J. J. et al. Navitoclax enhances the effectiveness of EGFR-targeted antibody–drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Res. 22, 132 (2020). · DOI
  155. Moore, K. N. et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann. Oncol. 32, 757–765 (2021). · DOI
  156. Moore, K. N. et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: initial report of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-α expression. J. Clin. Oncol. 41, LBA5507 (2023). · DOI
  157. Conilh, L., Sadilkova, L., Viricel, W. & Dumontet, C. Payload diversification: a key step in the development of antibody–drug conjugates. J. Hematol. Oncol. 16, 3 (2023). · DOI · Paper page
  158. Tolcher, A., Hamilton, E. & Coleman, R. L. The evolving landscape of antibody–drug conjugates in gynecologic cancers. Cancer Treat. Rev. 116, 102546 (2023). · DOI
  159. Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J. Clin. Oncol. 41, LBA3000 (2023). · DOI
  160. Shen, Y. A. et al. Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant ovarian cancers. Cancer Res. 80, 4514–4526 (2020). · DOI
  161. Wu, S. et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat. Cancer 2, 189–200 (2021). · DOI
  162. Harding, J. J. et al. A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors. Clin. Cancer Res. 27, 4994–5003 (2021). · DOI
  163. Cornelison, R. et al. Targeting RNA-polymerase I in both chemosensitive and chemoresistant populations in epithelial ovarian cancer. Clin. Cancer Res. 23, 6529–6540 (2017). · DOI
  164. Gourley, C. et al. Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J. Clin. Oncol. 28, 2505–2511 (2010). · DOI
  165. von Gruenigen, V. E. et al. The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group study. Gynecol. Oncol. 124, 379–382 (2012). · DOI
  166. Carey, M. S. et al. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol. Oncol. 108, 100–105 (2008). · DOI
  167. Bhat, G., Karakasis, K. & Oza, A. M. Measuring quality of life in ovarian cancer clinical trials—can we improve objectivity and cross trial comparisons? Cancers 12, 3296 (2020). · DOI
  168. Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018). · DOI · Paper page
  169. Monk, B. J. et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45). J. Clin. Oncol. 40, 3952–3964 (2022). · DOI
  170. Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1275–1289 (2021). · DOI
  171. Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22, 1034–1046 (2021). · DOI
  172. Kurtz, J. E. et al. Phase III ATALANTE/ov29 Trial: Atezolizumab (Atz) versus Placebo with Platinum-Based Chemotherapy (Cx) Plus Bevacizumab (Bev) in Patients (Pts) with Platinum-Sensitive Relapse (PSR) of Epithelial Ovarian Cancer (OC) (ESMO, 2022). · DOI
  173. Liu, J. F. et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol. 5, 1731–1738 (2019). · DOI
  174. Matulonis, U. A. et al. 949P Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRa)-Targeting Antibody-Drug Conjugate (ADC), with Pembrolizumab in Platinum-Resistant Ovarian Cancer (PROC): Initial Results of an Expansion Cohort from FORWARD II, a Phase Ib Study (ESMO, 2018). · DOI
  175. Lee, J. M. et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol. 19, 207–215 (2018). · DOI
  176. Konstantinopoulos, P. A. et al. A phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecol. Oncol. 167, 213–225 (2022). · DOI
  177. Fu, S. et al. Phase II Trial of the WEE1 Inhibitor Adavosertib in Advanced Refractory Solid Tumors with CCNE1 Amplification. (AACR, 2021). · DOI
  178. Westin, S. N. et al. EFFORT: efficacy of adavosertib in PARP resistance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. J. Clin. Oncol. 39, 5505 (2021). · DOI
  179. Leijen, S. et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J. Clin. Oncol. 34, 4354–4361 (2016). · DOI
  180. Oza, A. M. et al. An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer. J. Clin. Oncol. 33, 5506 (2015). · DOI
  181. Shah, P. D. et al. Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol. Oncol. 163, 246–253 (2021). · DOI
  182. Wethington, S. L. et al. Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer. J. Clin. Oncol. 39, 5516 (2021). · DOI
  183. Do, K. T. et al. Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors. Clin. Cancer Res. 27, 4710–4716 (2021). · DOI
  184. Hamilton, E. P. et al. 836P safety and efficacy of XMT-1536 in ovarian cancer: a subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody–drug conjugate. Ann. Oncol. 31, S627–S628 (2020). · DOI
  185. Gerber, D. E. et al. Phase Ia study of anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin DNIB0600A in patients with non-small cell lung cancer and platinum-resistant ovarian cancer. Clin. Cancer Res. 26, 364–372 (2020). · DOI
  186. Liu, J. et al. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol. Oncol. 163, 473–480 (2021). · DOI
  187. Hassan, R. et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody–drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J. Clin. Oncol. 38, 1824–1835 (2020). · DOI
  188. Rottey, S. et al. Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. Clin. Cancer Res. 28, 95–105 (2022). · DOI
  189. Hamilton, E. P. et al. Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC). J. Clin. Oncol. 40, 3002 (2022). · DOI

Cited by

Sorted by citations

Metadata

Authors
Konstantinopoulos, P. A., & Matulonis, U. A.
Venue
Nature Cancer
Publisher
Springer Science and Business Media LLC
Published
2023-08-31
Volume
4
Issue
9
Pages
1239-1257
ISSN
2662-1347
DOI
10.1038/s43018-023-00617-9
Cited by
394
References
10
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review